Recent

% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • vbm62 vbm62 Oct 15, 2003 3:52 PM Flag

    asked about 40 vs. 31%

    "The Phase III trial to determine if Antegren� (natalizumab) induces remission in moderate to severe Crohn's disease, known as ENACT-1, is now completed. Elan Corporation announced on Thursday, July 24 that the trial did not meet the primary endpoint of response, which was defined as a 70 point drop in the Crohn's Disease Activity Index (CDAI) at week 10. This result appears to be due to a larger than expected placebo response rate, A PHENOMENON seen in other Crohn's disease trials over the past few years..."

    from CCFA

 
ELN
0.00(0.00%)